WO1999051727A3 - Menschliche nukleinsäuresequenzen aus ovarnormalgewebe - Google Patents

Menschliche nukleinsäuresequenzen aus ovarnormalgewebe Download PDF

Info

Publication number
WO1999051727A3
WO1999051727A3 PCT/DE1999/001070 DE9901070W WO9951727A3 WO 1999051727 A3 WO1999051727 A3 WO 1999051727A3 DE 9901070 W DE9901070 W DE 9901070W WO 9951727 A3 WO9951727 A3 WO 9951727A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid sequences
human nucleic
ovary tissue
normal ovary
Prior art date
Application number
PCT/DE1999/001070
Other languages
English (en)
French (fr)
Other versions
WO1999051727A2 (de
Inventor
Thomas Specht
Bernd Hinzmann
Armin Schmitt
Christian Pilarsky
Edgar Dahl
Andre Rosenthal
Original Assignee
Metagen Gesellschaft Fuer Genomforschung Mbh
Thomas Specht
Bernd Hinzmann
Armin Schmitt
Christian Pilarsky
Edgar Dahl
Andre Rosenthal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Gesellschaft Fuer Genomforschung Mbh, Thomas Specht, Bernd Hinzmann, Armin Schmitt, Christian Pilarsky, Edgar Dahl, Andre Rosenthal filed Critical Metagen Gesellschaft Fuer Genomforschung Mbh
Priority to JP2000542440A priority Critical patent/JP2002510486A/ja
Priority to EP99944132A priority patent/EP1068231A2/de
Publication of WO1999051727A2 publication Critical patent/WO1999051727A2/de
Publication of WO1999051727A3 publication Critical patent/WO1999051727A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Es werden menschliche Nukleinsäuresequenzen - mRNA, cDNA, genomische Sequenzen - aus Ovarnormalgewebe, die für Genprodukte oder Teile davon kodieren, und deren Verwendung beschrieben. Es werden weiterhin die über die Sequenzen erhältlichen Polypeptide und deren Verwendung beschrieben.
PCT/DE1999/001070 1998-04-03 1999-03-31 Menschliche nukleinsäuresequenzen aus ovarnormalgewebe WO1999051727A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000542440A JP2002510486A (ja) 1998-04-03 1999-03-31 正常卵巣組織からのヒト核酸配列
EP99944132A EP1068231A2 (de) 1998-04-03 1999-03-31 Menschliche nukleinsäuresequenzen aus ovarnormalgewebe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816395.9 1998-04-03
DE19816395A DE19816395A1 (de) 1998-04-03 1998-04-03 Menschliche Nukleinsäuresequenzen aus Ovar-Normalgewebe

Publications (2)

Publication Number Publication Date
WO1999051727A2 WO1999051727A2 (de) 1999-10-14
WO1999051727A3 true WO1999051727A3 (de) 2000-07-06

Family

ID=7864421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/001070 WO1999051727A2 (de) 1998-04-03 1999-03-31 Menschliche nukleinsäuresequenzen aus ovarnormalgewebe

Country Status (4)

Country Link
EP (1) EP1068231A2 (de)
JP (1) JP2002510486A (de)
DE (1) DE19816395A1 (de)
WO (1) WO1999051727A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
WO2001000803A2 (en) * 1999-06-25 2001-01-04 Genset Apolipoprotein a-iv-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
EP1144444A3 (de) * 1998-12-22 2002-01-02 Genset Kodierende nuleinsäuren für proteine mit signalsequenzen
US6455280B1 (en) 1998-12-22 2002-09-24 Genset S.A. Methods and compositions for inhibiting neoplastic cell growth
US6573069B1 (en) 1999-11-10 2003-06-03 Zymogenetics, Inc. Crib protein ZMSE1
CA2390491A1 (en) * 1999-11-10 2001-05-17 Zymogenetics, Inc. Crib protein zmse1
US7229758B2 (en) 2001-02-26 2007-06-12 Mulder Kathleen M Control of TGFβ signaling by km23 superfamily members
EP1287027A2 (de) * 2000-02-25 2003-03-05 Kathleen M. Mulder Kontrolle der tgf(beta)-vermittelten signaltransduktion durch mitglieder der km23-superfamilie
WO2001096391A2 (en) * 2000-06-13 2001-12-20 Agensys, Inc. 55p4h4: gene expressed in various cancers
GB0105402D0 (en) * 2001-03-05 2001-04-18 Inpharmatica Ltd Novel proteins
WO2003006479A1 (en) * 2001-07-13 2003-01-23 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
EP1491895A1 (de) * 2003-06-24 2004-12-29 Universitätsklinikum Freiburg Modulierung der Osteoblast-Aktivität durch Fhl2
US7741299B2 (en) 2004-08-16 2010-06-22 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
GB2450840B (en) 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
EP2026843A4 (de) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutische verwendungen von rtp801l
EP2137205A2 (de) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitoren von rtp801 und ihre verwendung bei der behandlung von krankheiten
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2019045149A1 (en) * 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL/GENBANK 14 November 1997 (1997-11-14), SHUGRUE, C.A. ET AL.: "Rattus norvegicus vesicle associated protein (VAP1) mRNA", XP002128356 *
DATABASE EMBL/GENBANK 16 August 1996 (1996-08-16), MASSART, C. ET AL.: "H. Sapiens mRNA (EST; from fetal brain)", XP002128358 *
DATABASE EMBL/GENBANK 3 July 1997 (1997-07-03), HILLIER, L. ET AL.: "Soares ovary tumor NbHOT Homo sapiens cDNA clone 755776 (EST)", XP002128357 *
HENRIKSEN, R. ET AL.: "Expression and prognostik significance of TGF-beta isotypes ...", LABORATORY INVESTIGATION, vol. 73, no. 2, 1995, pages 213 - 220, XP002128353 *
HIRTE, H.W. ET AL.: "Differntial display of mRNA ...", PROC. AM. ASS. CANCER RES., vol. 36, no. 0, 1995, pages 184, XP002128354 *
MOK, S.C. ET AL.: "Molecular cloning of differentially expressed genes in human epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, vol. 52, 1994, pages 247 - 252, XP002128355 *
SHUGRUE ET AL.: "Antibodies to an epitope on synapsin I ...", EUR. J. CELL BIOL., vol. 65, no. (2), 1994, pages 327 - 340 *
YU, W. ET AL.: "Large-scale concatenation cDNA sequencing", GENOME RESEARCH, vol. 7, 1997, pages 353 - 358, XP002128368 *
YU, Y.H. ET AL.: "Differntial display of genes expressed in normal ovarian surface epithelium ...", PROC. AM ASS. CANCER RES., vol. 37, no. 0, 1997, pages 592, XP002074635 *

Also Published As

Publication number Publication date
JP2002510486A (ja) 2002-04-09
DE19816395A1 (de) 1999-10-07
WO1999051727A2 (de) 1999-10-14
EP1068231A2 (de) 2001-01-17

Similar Documents

Publication Publication Date Title
WO1999054461A3 (de) Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe
WO1999051727A3 (de) Menschliche nukleinsäuresequenzen aus ovarnormalgewebe
WO1999047669A3 (de) Menschliche nukleinsäuresequenzen aus brusttumorgewebe
WO1999055858A3 (de) Menschliche nukleinsäuresequenzen aus pankreastumorgewebe
WO1999053040A3 (de) Menschliche nukleinsäuresequenzen aus ovartumorgewebe
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
WO1999053051A3 (en) 5' ests and encoded human proteins
EP1440981A3 (de) Vollständige humane cDNS
WO1999054353A3 (de) Menschliche nukleinsäuresequenzen aus uterusnormalgewebe
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO1999054460A3 (de) Menschliche nukleinsäuresequenzen aus normalem blasengewebe
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
WO1999054447A3 (de) Menschliche nukleinsäuresequenzen aus blasentumorgewebe
WO2001016377A3 (en) Diagnostics and therapeutics for osteoporosis
WO1999046374A3 (de) Menschliche nukleinsäuresequenzen aus prostatatumorgewebe
WO1999047655A3 (de) Menschliche nukleinsaeurefragmente, deren expression in brustnormalgewebe erhöht ist
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO1999046375A3 (de) Menschliche nukleinsäuresequenzen aus prostatagewebe
WO1998033937A3 (de) GENOMISCHE SEQUENZ DES HUMANEN ν-OPIOID-REZEPTOR GENES SOWIE SEINER VARIANTEN, POLYMORPHISMEN UND MUTATIONEN
WO1999054448A3 (de) Menschliche nukleinsäurefragmente, deren expression in uterusmyomgewebeerhoeht ist
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999944132

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09646777

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999944132

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999944132

Country of ref document: EP